Cancer Biologics Market Size 2024-2028

The cancer biologics market size is estimated to grow by USD 51.08 billion, at a CAGR of 9.18% between 2023 and 2028. The growth of the market is significantly driven by the focus on personalized medicines, marking a departure from the traditional one-size-fits-all model. Personalized medicine, tailored to the unique genetic testing and molecular characteristics of individual cancer patients, offers more targeted and effective therapies, particularly in the context of the heterogeneous nature of cancer. Biologics therapeutics, designed to interact with specific molecular targets, seamlessly align with the personalized medicine paradigm. Further, advancements in genomics and molecular profiling technologies contribute to a deeper understanding of the molecular intricacies of various cancers, facilitating the development that precisely intervenes in the pathways driving a particular patient's cancer. The growing recognition of inherent genetic diversity among patients fuels the demand for personalized treatments, driving the significant growth of the market during the forecast period.

What will be the Size of the Cancer Biologics Market During the Forecast Period?

To learn more about this market report, Download Report Sample

Cancer Biologics Market Segmentation

The cancer biologics market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024 to 2028, as well as historical data from 2018 to 2022 for the following segments.

• Product Outlook
  • Monoclonal antibodies
  • Cell and gene therapy
  • Vaccines
  • Others

• Route Of Administration Outlook
  • Injectable
  • Oral

• Region Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of World (ROW)
    • Brazil
    • Argentina 
    • Australia 

By Product 

The market share growth by the monoclonal antibodies segment will be significant during the forecast period. Monoclonal antibodies are an important part of targeted therapy or immunotherapy for the treatment. The monoclonal antibodies block tumor growth by acting on specific targets and preventing cancer progression or carcinogenesis. These targets are the cascade proteins that are responsible for angiogenesis. The monoclonal antibodies alter the way a cancer cell divides, repairs, grows, and interacts with other cells.

Get a glance at the market contribution of various segments. Download PDF Sample

The monoclonal antibodies segment was the largest and was valued at USD 51.65 billion in 2018. Some of the approved monoclonal antibodies available on the market include Herceptin, Avastin, MabThera/Rituxan, XGEVA, Vectibix, BLINCYTO, OPDIVO, EMPLICITI, YERVOY, LARTRUVO, PORTRAZZA, ERBITUX, CYRAMZA, PERJETA, KADCYLA, TECENTRIQ, GAZYVA, and KEYTRUDA. The growth momentum of the monoclonal antibodies segment is accelerating due to the new drug approvals, especially for immunotherapy drugs, as well as the presence of a large number of monoclonal antibodies in the pipeline for the treatment. The pipeline for biologics is dominated by monoclonal antibodies. Therefore, the presence of these monoclonal antibodies in the market are expected to contribute to the growth of the monoclonal antibodies segment of the market during the forecast period.

By Route Of Administration 

Injectable

The injectable route of administration is a common and well-established method for delivering cancer biologics. This approach involves introducing therapeutic agents directly into the bloodstream through various injection methods, such as intravenous (IV), subcutaneous (SC), or intramuscular (IM) injections. Injectable cancer biology often consists of large, complex molecules that necessitate precise delivery to ensure effective treatment. Several injectable cancer biologics have been developed for the treatment of various cancers. However, one challenge with injectable cancer biologics lies in the potential development of injection site reactions, which can include redness, swelling, or discomfort. These reactions are closely monitored during clinical trials and real-world use to ensure patient safety and optimize treatment outcomes. These factors are expected to contribute to the growth of the injectable segment of the market during the forecast period.

Oral

The oral route of administration for cancer biologics has emerged as a promising alternative to traditional methods such as intravenous injections. This approach involves delivering therapeutic agents in the form of oral medications, typically in the form of tablets or capsules. The appeal of oral administration lies in its convenience and potential to enhance patient compliance, as it eliminates the need for frequent hospital visits for intravenous treatments. Further, the potential benefits extend beyond patient convenience. This mode of administration may offer a more patient-friendly experience, reducing the burden of treatment on individuals battling cancer. Additionally, oral delivery could contribute to healthcare cost reduction by minimizing the need for specialized medical facilities and personnel required for intravenous administration. These factors are expected to contribute to the growth of the oral segment of the market during the forecast period.

By Region

For more insights about the market share of various regions, Download PDF Sample now!

North America is estimated to contribute 47% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The rising incidence of cancer in countries such as the US and Canada is driving the market in North America. The incidence of cancers such as breast cancer, esophageal cancer, pancreatic cancer, and gynecological cancers, along with rare cancers such as neuroblastoma, is continuously increasing. As per the CDC, about 237,000 cases of breast cancer are diagnosed in women and about 2,100 in men each year in the US. As per the NIH, it was estimated that about 650 children are diagnosed each year with neuroblastoma in the US. In addition to the rising incidence of cancer, the accelerated approvals granted by regulatory authorities such as the FDA are driving market growth.

Additionally, biologics such as monoclonal antibodies are covered under reimbursement schemes in the US. For example, UNITUXIN, an immunotherapy drug for the treatment of neuroblastoma is covered under Medicare Part B. The high prevalence of cancer and the availability of favorable reimbursement schemes are the factors contributing to the growth of the market in the US. Moreover, organizations such as the American Cancer Society, the American Breast Cancer Foundation (ABCF), and the Esophageal Cancer Awareness Association (ECAA) are taking initiatives to support patients, caregivers, survivors, family members, and anyone at risk of the disease. This, in turn, is driving the market in the region during the forecast period.

Cancer Biologics Market Dynamics

The market is rapidly evolving, driven by advancements in cancer biotechnology and a growing focus on innovative treatments. Unlike traditional chemotherapy, biologic drugs, including interleukins and cytokines, target cancer at the molecular level, offering more personalized and effective treatment options. Cell-Based Immunotherapies are becoming increasingly popular, providing new hope for patients. Reimbursement policies and insurance providers play a crucial role in making these treatments accessible. Hospital pharmacies, retail pharmacies, and online pharmacies are key distribution channels for these drugs. The market growth is also influenced by the increasing fatalities from cancer and the limitations of conventional treatments. As research continues, the development of biologic drugs derived from animal and human sources is expected to expand. Our researchers analyzed the data with 2023 as the base year, along with the key market growth analysis through drivers, trends, and challenges. 

Key Market Drivers

The rising global incidence of cancer is notably driving market growth. Cancer is one of the most common chronic diseases and is becoming a major health issue as it is increasing the mortality rate globally. Major factors that lead to cancer include genetic mutations, environmental factors such as tobacco smoking and pollution, and changing dietary patterns. The rising prevalence of these factors has directly contributed to the increased global incidence of cancer. As a result, cancer has become the second leading cause of death worldwide. In 2020, there were 19.3 million new cancer cases and 10 million cancer-related deaths worldwide.

Moreover, healthcare providers need data related to cancer incidences to make decisions regarding the volume of equipment and medicines to be purchased for treatment and to develop awareness and prevention programs. Therefore, the rising incidence and prevalence of cancer among the population are expected to increase the demand for cancer biologics. Thus, the rapidly rising incidence throughout the world is a major factor that will drive cancer biologics market growth during the forecast period.

Significant Market Trends

The untapped potential of cancer biologics in developing countries is an emerging trend shaping market growth. Cancer is a deadly epidemic disease across the globe; however, the condition is turning out to be a major killer in developing countries. Cancers are more common in developing countries. Countries such as India, China, and Brazil are garnering the attention of many global pharmaceutical companies dealing with oncology drugs. Many factors, such as the large global population and the rising geriatric population, are driving the growth of the healthcare sector significantly in developing countries.

In addition, developing countries, especially South Asian countries such as India and China, are heavily dependent on chemotherapy drugs for cancer treatment. As chemotherapy drugs have many side effects, consumer preference is expected to increase in Asia and other developing regions. These factors will drive cancer biologics market growth and trends during the forecast period.

Major Market Challenges

Patent expiry of major cancer biologics is a significant challenge hindering market growth. The expiry of the patent for a particular drug paves the way for the emergence of its low-priced generic versions in the market. In the case of biologics, the low-priced generic versions are referred to as biosimilars. A biosimilar (also known as a follow-on biologic or subsequent entry biologic) is an identical version of the bio-originator product and has similar pharmacokinetic and pharmacological properties.

Moreover, the biosimilar versions of most of the cancer biologics, which have faced patent expiration, have already entered the market. Hence, the emergence of biosimilars due to patent expiration of biologics is expected to hinder cancer biologics market growth during the forecast period.

Customer Landscape

The cancer biologics market forecasting report includes the adoption lifecycle of the market research and growth, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the cancer biologics market analysis and report also include key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth and forecasting strategies.

 Customer Landscape

Key Cancer Biologics Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

Amgen Inc. - The company offers cancer biologics under the brand name Lumakras. This is offered for patients with KRAS G12C mutated advanced colorectal cancer CRC.

• AstraZeneca Plc
• Bayer AG
• Biocon Ltd.
• Biogen Inc.
• Bristol Myers Squibb Co.
• Celltrion Co. Ltd
• Cipla Ltd.
• Dr Reddys Laboratories Ltd.
• Eli Lilly and Co.
• F. Hoffmann La Roche Ltd.
• Gilead Sciences Inc.
• GlaxoSmithKline Plc
• Jazz Pharmaceuticals Plc.
• Johnson and Johnson
• Lupin Ltd.
• Merck KGaA
• Novartis AG
• Ono Pharmaceutical Co. Ltd.
• Viatris Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Analyst Overview

The cancer biologics market is witnessing exponential growth, driven by the increasing demand for innovative treatments and advancements in biotechnology. Biologic drugs sourced from living organisms such as animals, humans, and microorganisms offer targeted therapies, including monoclonal antibodies, vaccines, cells, allergens, tissues, genes, and recombinant proteins. Regulatory bodies like the FDA play a crucial role, with 47 biologics receiving novel indications, particularly in oncology, with 20 approvals in 2019 alone. Clinical trials exploring diverse modalities like adoptive cell transfer, gene therapy, and immunotherapy are reshaping cancer diagnostics. Targeted approaches such as angiogenesis inhibitors and chimeric antigen receptor (CAR) T-cell therapy are gaining prominence. Companies like Ologics and CUSABIO are driving innovation in this competitive landscape.

Segment-wise, monoclonal antibodies, growth factors, blood products, vaccines, and toxoids dominate the market. Techniques like immunohistochemistry and next-generation sequencing are facilitating personalized medicine approaches. Medications like Herceptin, Avastin, Rituxan, and Remicade are pivotal in cancer management. Collaborations with organizations like the FDA and EMA ensure stringent regulatory compliance and quality assurance. With advancements in genomics and targeted drug therapy, the market continues to evolve, offering hope for improved patient outcomes. Immunotherapy and breast cancer therapeutics are witnessing significant growth. As demand for advanced cancer treatments increases, particularly in North America, Europe, and Asia, the biologics market is playing a pivotal role. Innovations in biologics, driven by the rise in breast cancer cases, are boosting the CDMO market. The evolving landscape in regions like the US, Germany, and China is expected to further fuel the growth of cancer biologics, shaping the future of cancer treatment.

The cancer biologics market is experiencing significant growth, driven by advancements in therapeutic products and cell-based therapies targeting cancer cells and tumor growth signals. Biotechnology advancements, including HER2-targeted antibodies, EGFR inhibitors, and immune checkpoint inhibitors, are enhancing immune responses against cancers like leukemia, lymphoma, and multiple myeloma. CAR-T cell therapies, antibody-dependent cellular cytotoxicity, and phagocytosis are transforming the blood cancer segment. Oncology biologics, such as bispecific antibodies and biologic therapies, are increasingly used in specialized hospitals and cancer centers by medical oncologists, hematologists, and radiation oncologists. The aging population and lifestyle changes contribute to rising cancer incidence, driving research and development efforts at academic institutions and biotechnology firms. Regulatory environments, healthcare expenditure, and patent expirations further shape the market. Treatment for lung, liver, nasopharyngeal, and prostate cancers is advancing, though side effects like allergic reactions, diarrhea, nausea, vomiting, and rash remain concerns.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Cancer Biologics Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting of the market between 2024 and 2028
• Precise estimation of the size of the market size and its contribution to the parent market
• Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
• Growth of the market industry across Europe, North America, APAC, South America, and Middle East and Africa
• Thorough market growth analysis of the market's competitive landscape and detailed information about companies
• Comprehensive market analysis and report on the factors that will challenge the market research and growth of market companies

We can help! Our analysts can customize this cancer biologics market research and growth report to meet your requirements. Get in touch